TP53 and ovarian cancer: The inhibition of either ERCC1 or XPF expression by siRNA in p53 wt (A2780, 3–6% vs. 20% survival at 10 μM) and p53-mutated (PEO4, <1% vs. 80% survival at 2 μM) ovarian cancer cells increased the sensitivity to olaparib [29].